Secondary Stock OfferingsBy The Online Investor Staff, updated Thu., Feb. 27, 2:35 PM
|This Slide: #9 of 25|
Slide #9. Agile Therapeutics, Inc. — Secondary Offering
Agile Therapeutics, Inc. (NASDAQ:AGRX)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 2/21- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering will be sold by Agile Therapeutics.
Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, also known as AG200-15, is a once-weekly prescription combination hormonal contraceptive patch that is at the end of clinical development. Twirla is a combined hormonal contraceptives patch that contains the active ingredients ethinyl estradiol, which is a synthetic estrogen, and levonorgestrel, which is a type of progestin, a synthetic steroid hormone. Co. also has a pipeline of other transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle, and AG200-SP, which is a regimen designed to provide shorter lighter periods.
Open the AGRX Page at The Online Investor »
Strong Buy (3.83 out of 4)
(ranked higher than approx. 77% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite